Physician profile
Michael C Dillon
NPI 1285600148
$1,062.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $257 · 2022: $437.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $270.74 | 2022 | |
| Amgen INC. | $270.35 | 2019-2022 | |
| Amarin Pharma, INC. | $129.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $84.99 | 2019-2022 | |
| Pfizer INC. | $69.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $43.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $25.14 | 2019 | |
| Astellas Pharma US INC | $21.40 | 2020 | |
| Philips North America LLC | $19.97 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.55 | 2019 | |
| Merck Sharp & Dohme LLC | $13.69 | 2022 | |
| Gilead Sciences, INC. | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.